Related Experiment Video
Updated: May 29, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Synthetic lethality of mRNA quality control complexes in cancer
Vivian Prindle1, Adam E Richardson1, Kimberly R Sher1
1AbbVie, North Chicago, IL, USA.
Abstract:
Synthetic lethality exploits the genetic vulnerabilities of cancer cells to enable a targeted, precision approach to treat cancer1. Over the past 15 years, synthetic lethal cancer target discovery approaches have led to clinical successes of PARP inhibitors2 and ushered several next-generation therapeutic targets such as WRN3, USP14, PKMYT15, POLQ6 and PRMT57 into the clinic. Here we identify, in human cancer, a novel synthetic lethal interaction between the PELO-HBS1L and SKI complexes of the mRNA quality control pathway. In distinct genetic contexts, including 9p21.3-deleted and high microsatellite instability (MSI-H) tumours, we found that phenotypically destabilized SKI complex leads to dependence on the PELO-HBS1L ribosomal rescue complex. PELO-HBS1L and SKI complex synthetic lethality alters the normal cell cycle and drives the unfolded protein response through the activation of IRE1, as well as robust tumour growth inhibition. Our results indicate that PELO and HBS1L represent novel therapeutic targets whose dependence converges upon SKI complex destabilization, a common phenotypic biomarker in diverse genetic contexts representing a significant population of patients with cancer.
Insights
Synthetic lethality identifies new cancer targets. Targeting the PELO-HBS1L and SKI complexes inhibits tumor growth by exploiting cancer cell vulnerabilities.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Synthetic lethality is a precision cancer treatment strategy.
- PARP inhibitors are a successful example of synthetic lethality.
- Several novel targets are advancing in clinical trials.
Purpose of the Study:
- Identify novel synthetic lethal interactions in human cancer.
- Investigate the PELO-HBS1L and SKI complex interaction within the mRNA quality control pathway.
- Determine the therapeutic potential of targeting this interaction.
Main Methods:
- Analysis of distinct genetic contexts, including 9p21.3-deleted and high microsatellite instability (MSI-H) tumors.
- Characterization of the PELO-HBS1L and SKI complex interplay.
- Assessment of cell cycle alterations and unfolded protein response activation.
Main Results:
- A novel synthetic lethal interaction was identified between PELO-HBS1L and SKI complexes.
- SKI complex destabilization leads to dependence on the PELO-HBS1L ribosomal rescue complex in specific tumor types.
- This synthetic lethality activates the unfolded protein response via IRE1 and inhibits tumor growth.
Conclusions:
- PELO and HBS1L are potential novel therapeutic targets in cancer.
- SKI complex destabilization serves as a biomarker for this synthetic lethality.
- This approach targets a significant patient population across diverse genetic contexts.
Related Concept Videos
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Nuclear Export of mRNA
MicroRNAs
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
Regulation of Expression at Multiple Steps
RNA Splicing

